RESEARCH & DEVELOPMENT
ACTIVITIES
ACTIVITIES
Beyond the mission of our scientific team to develop therapeutic products for regenerative medicine as well as innovative cell and tissue platform technologies, we are committed to the refinement of existing and the development of new strategies for tissue regeneration.
With knowledge of the requirements and in cooperation with our clinical partners, TransTissue develops treatment strategies and products which can easily be implemented in clinical practice.
Focusing on the 2nd and 3rd generations of soft and hard tissue repair, TransTissue has developed novel and innovative cell-based transplants and cell-free implants.
Cell-based applications spotlight therapies for osteoarthritic cartilage and jawbone defects and are based on autologous mesenchymal cells. Cell-free applications are based on the recruitment of mesenchymal stem and progenitor cells to a defective site and their guidance to regenerate this tissue.
Finally, with our in vitro model of rheumatoid arthritis (“pannus model”), we are enhancing a test system aimed at high-throughput screening of anti-rheumatic candidate drugs.
With knowledge of the requirements and in cooperation with our clinical partners, TransTissue develops treatment strategies and products which can easily be implemented in clinical practice.
Focusing on the 2nd and 3rd generations of soft and hard tissue repair, TransTissue has developed novel and innovative cell-based transplants and cell-free implants.
Cell-based applications spotlight therapies for osteoarthritic cartilage and jawbone defects and are based on autologous mesenchymal cells. Cell-free applications are based on the recruitment of mesenchymal stem and progenitor cells to a defective site and their guidance to regenerate this tissue.
Finally, with our in vitro model of rheumatoid arthritis (“pannus model”), we are enhancing a test system aimed at high-throughput screening of anti-rheumatic candidate drugs.